Literature DB >> 23977769

Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.

Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23977769      PMCID： PMC4821411     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  7 in total

1.  Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.

Authors:  Ohad Benjamini; Preetesh Jain; Zeev Estrov; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

2.  Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.

Authors:  Holly Geyer; Keith Cannon; Emily Knight; Veena Fauble; John Camoriano; Robyn Emanuel; Raoul Tibes; Ruben Mesa
Journal:  Leuk Lymphoma       Date:  2013-06-12

3.  Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Authors:  Ruben A Mesa; Jason Gotlib; Vikas Gupta; John V Catalano; Michael W Deininger; Alan L Shields; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Thomas Hare; Susan Erickson-Viitanen; William Sun; Victor Sandor; Richard S Levy; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

Review 4.  Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.

Authors:  Srdan Verstovsek
Journal:  Postgrad Med       Date:  2013-01       Impact factor: 3.840

Review 5.  A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis.

Authors:  John Mascarenhas; Ronald Hoffman
Journal:  Blood       Date:  2013-04-09       Impact factor: 22.113

Review 6.  Clarifying the use of ruxolitinib in patients with myelofibrosis.

Authors:  Marina Kremyanskaya; Ehab L Atallah; Ronald Hoffman; John O Mascarenhas
Journal:  Oncology (Williston Park)       Date:  2013-07       Impact factor: 2.990

Review 7.  Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib.

Authors:  J Mascarenhas; T I Mughal; S Verstovsek
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530
  7 in total
  1 in total

1.  Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.

Authors:  William L Heaton; Anna V Senina; Anthony D Pomicter; Mohamed E Salama; Phillip M Clair; Dongqing Yan; Russell N Bell; Jeremy M Gililland; Josef T Prchal; Thomas O'Hare; Michael W Deininger
Journal:  Leukemia       Date:  2018-04-18       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.